Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented small cell carcinoma of the bronchus, classified as extensive-stage disease~* Measurable disease or lesions~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~Exclusion Criteria:~* Life expectancy of \< 12 weeks~* Current, recent, or planned participation in another experimental drug study~* Ongoing or active infection~* Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within the previous 5 years~* Prior systemic therapy, radiation therapy, or surgery for SCLC~* Inadequate bone marrow function, renal function, or hepatic function~* Serum sodium of \< 120 mg/dL~* Inadequately controlled hypertension~* History of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association Class II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Known central nervous system disease, except for brain metastases treated with whole-brain radiotherapy~* Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to study enrollment~* History of hemoptysis within 4 weeks prior to study enrollment~* Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of a need for a major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, including placement of a vascular access device, within 7 days prior to Day 1~* History of abdominal fistula or gastrointestinal perforation within 6 months prior to study enrollment~* Serious, non-healing wound, active ulcer, or untreated bone fracture~* Known hypersensitivity to any component of bevacizumab~* Pregnant (positive pregnancy test) or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo+Chemotherapy (Type: PLACEBO_COMPARATOR): Chemotherapy = cisplatin (or carboplatin) + etoposide
- Bevacizumab+Chemotherapy (Type: EXPERIMENTAL): Chemotherapy = cisplatin (or carboplatin) + etoposide

Based on this trial design, predict the completion outcome and termination type (if applicable).